Covered FDA-Approved Indications and Compendial Uses
Covered when the requested therapy is an FDA-approved indication or covered compendial use, all applicable approval criteria are met, and the member has no exclusion to the prescribed therapy.
ALL of the following
The requested medication is used for an indication listed in the coverage criteria.
All disease, biomarker, treatment-setting, and regimen requirements for the applicable indication are met.
The member has no applicable exclusion.
Cutaneous Melanoma
Authorization of 6 months may be granted when ALL applicable criteria are met.
ANY of the following settings
Unresectable or metastatic melanoma treated as a single agent.
Subsequent therapy for metastatic or unresectable disease in combination with lenvatinib.
Neoadjuvant treatment as a single agent.
Adjuvant treatment following complete lymph node resection or complete resection of stage IIB, IIC, or III disease as a single agent in a member age 12 years or older.
Subsequent or re-induction therapy in combination with trametinib and dabrafenib for metastatic or unresectable disease with a BRAF V600 activating mutation.
Non-Small Cell Lung Cancer
Authorization of 6 months may be granted for recurrent, advanced, or metastatic NSCLC when applicable molecular testing requirements and one covered treatment pathway are met.
ALL of the following
There are no EGFR exon 19 deletions or exon 21 L858R mutations, or ALK, RET, or ROS1 gene fusions, unless testing is not feasible because of insufficient tissue.
ANY of the following
Single-agent treatment for PD-L1-positive disease.
Single-agent treatment or treatment in combination with pemetrexed for maintenance therapy.
Combination with pemetrexed and carboplatin or cisplatin for nonsquamous histology.
Head and Neck Cancer
Authorization of 6 months may be granted when the disease setting, biomarker, and treatment requirements are met.
ANY of the following
Resectable stage III-IVa non-nasopharyngeal HNSCC with PD-L1 ≥1, treated as a single agent neoadjuvantly, then with radiotherapy with or without cisplatin as adjuvant therapy, followed by single-agent therapy.
Very advanced HNSCC, mixed-subtype HNSCC, or nasopharyngeal cancer treated as a single agent first line for PD-L1 CPS ≥1, MSI-H, dMMR, or TMB-H ≥10 mut/Mb disease.
Very advanced HNSCC, mixed-subtype HNSCC, or nasopharyngeal cancer treated as single-agent subsequent therapy.
Very advanced HNSCC, mixed-subtype HNSCC, or nasopharyngeal cancer treated in combination with cetuximab or chemotherapy.
Recurrent salivary gland tumors that are MSI-H, dMMR, TMB-H ≥10 mut/Mb, or PD-L1 positive, treated as a single agent.
Non-Small Cell Lung Cancer — Neoadjuvant or Adjuvant Use
Authorization of 6 months may be granted for qualifying resectable NSCLC.
ALL of the following
The disease is resectable, with tumors ≥4 cm or node-positive disease.
The requested medication is used neoadjuvantly with platinum-containing chemotherapy or as adjuvant single-agent therapy after adjuvant chemotherapy or qualifying neoadjuvant therapy.
There are no EGFR exon 19 deletions or exon 21 L858R mutations, or ALK, RET, or ROS1 gene fusions, unless testing is not feasible because of insufficient tissue.
Head and Neck Cancer — Covered Disease Settings
Authorization of 6 months may be granted for covered HNSCC disease settings.
ANY of the following
Resectable stage III-IVa non-nasopharyngeal HNSCC with PD-L1 ≥1, using neoadjuvant single-agent therapy, adjuvant radiotherapy with or without cisplatin, and subsequent single-agent therapy.
Very advanced HNSCC or mixed-subtype HNSCC treated as first-line single-agent therapy for PD-L1 CPS ≥1, MSI-H, dMMR, or TMB-H ≥10 mut/Mb disease.
Very advanced HNSCC or mixed-subtype HNSCC treated as subsequent single-agent therapy or in combination with cetuximab or chemotherapy.
Nasopharyngeal cancer treated under one of the preceding covered pathways.
Recurrent salivary gland tumor that is MSI-H, dMMR, TMB-H ≥10 mut/Mb, or PD-L1 positive, treated as a single agent.
Urothelial Carcinoma
Authorization of 6 months may be granted for urothelial carcinoma in any qualifying disease location and treatment setting.
ANY of the following
Bladder urothelial carcinoma: stage II, recurrent, locally advanced, or metastatic disease treated first line, subsequently, or adjuvantly; or high-risk BCG-unresponsive NMIBC with CIS when the member will not undergo cystectomy.
Primary urethral carcinoma: locally advanced, recurrent, or metastatic disease when not eligible for platinum chemotherapy; recurrent or metastatic disease after platinum or other chemotherapy; or adjuvant therapy.
Upper genitourinary tract urothelial carcinoma: metastatic disease when not eligible for platinum chemotherapy; metastatic disease after platinum or other chemotherapy; or adjuvant therapy after platinum-based neoadjuvant chemotherapy.
Urothelial carcinoma of the prostate: metastatic disease when not eligible for platinum chemotherapy; metastatic disease after platinum or other chemotherapy; or adjuvant therapy when platinum-based neoadjuvant chemotherapy was not given.
Biomarker-Positive Solid Tumors
Authorization of 6 months may be granted as a single agent when ALL criteria are met.
ALL of the following
The tumor is an unresectable or metastatic solid tumor that has progressed following prior treatment.
There is no satisfactory alternative treatment option.
The tumor meets ONE of these biomarker criteria
Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).
Tumor mutational burden-high (TMB-H), ≥10 mutations/megabase.
Anaplastic Thyroid Carcinoma
Authorization of 6 months may be granted as a single agent or in combination with lenvatinib.
ALL of the following
The diagnosis is stage IVC anaplastic thyroid carcinoma.
The requested medication is used as a single agent or with lenvatinib.
Follicular, Oncocytic, or Papillary Thyroid Carcinoma
Authorization of 6 months may be granted when ALL criteria are met.
ALL of the following
The disease is follicular, oncocytic (Hürthle cell), or papillary thyroid carcinoma and is locoregional, unresectable, progressive and/or symptomatic, or metastatic.
Radioactive iodine therapy is not indicated, contraindicated, or has been unsuccessful.
ONE of the following
The disease is MSI-H, dMMR, or TMB-H ≥10 mut/Mb.
The disease progressed on single-agent lenvatinib and the requested medication will be combined with lenvatinib.
Colorectal Cancer
Authorization of 6 months may be granted as a single agent.
ALL of the following
The diagnosis is colorectal cancer, including appendiceal neoplasm or carcinoma.
The tumor has ONE of the following biomarker profiles
POLE/POLD1 mutation with an ultra-hypermutated phenotype, TMB >50 mut/Mb.
Small Bowel Adenocarcinoma
Authorization of 6 months may be granted as a single agent in any qualifying small bowel adenocarcinoma setting.
ANY of the following
Neoadjuvant therapy for MSI-H, dMMR, or POLE/POLD1 ultra-hypermutated tumors with TMB >50 mut/Mb.
Unresectable or medically inoperable disease with MSI-H, dMMR, or POLE/POLD1 ultra-hypermutated tumors with TMB >50 mut/Mb.
Advanced or metastatic disease with TMB-H ≥10 mut/Mb, MSI-H, dMMR, or POLE/POLD1 ultra-hypermutated tumors with TMB >50 mut/Mb.
Merkel Cell Carcinoma
Authorization of 6 months may be granted as a single agent.
ALL of the following
The member is age 12 years or older.
The disease is locally advanced, regional, recurrent, or metastatic Merkel cell carcinoma.
Cervical Cancer
Authorization of 6 months may be granted in any qualifying setting.
ANY of the following
Persistent, recurrent, or metastatic disease treated with chemotherapy with or without bevacizumab for PD-L1 CPS ≥1 disease.
Recurrent or metastatic disease treated as a single agent or with tisotumab vedotin-tftv as subsequent therapy for PD-L1 CPS ≥1 or MSI-H/dMMR disease.
FIGO stage III-IVA disease treated with chemoradiation.
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Authorization of 6 months may be granted for the following ovarian, fallopian tube, primary peritoneal, and related histologies.
ANY of the following
Single-agent treatment for recurrent or persistent MSI-H, dMMR, or TMB-H ≥10 mut/Mb epithelial ovarian, fallopian tube, primary peritoneal, carcinosarcoma, clear cell, mucinous, grade 1 endometrioid, low-grade serous, or malignant germ cell tumors.
Combination with oral cyclophosphamide and bevacizumab for recurrent or persistent epithelial ovarian, fallopian tube, primary peritoneal, carcinosarcoma, clear cell, mucinous, grade 1 endometrioid, or low-grade serous carcinoma.
Subsequent treatment of platinum-resistant or recurrent disease in combination with paclitaxel, with or without bevacizumab, when PD-L1 CPS ≥1.
Single-agent treatment for progressive or recurrent small cell carcinoma of the ovary, hypercalcemic type.
Uveal Melanoma
Authorization of 6 months may be granted as a single agent.
ALL of the following
The disease is unresectable or metastatic uveal melanoma.
Endometrial Carcinoma
Authorization of 6 months may be granted in any qualifying endometrial carcinoma pathway.
ANY of the following
Combination with lenvatinib for advanced, metastatic, or recurrent pMMR endometrial carcinoma.
Combination with lenvatinib for dMMR endometrial carcinoma that progressed after platinum-based chemotherapy.
Single-agent treatment for recurrent unresectable or metastatic MSI-H, dMMR, or TMB-H ≥10 mut/Mb disease.
Combination with carboplatin and paclitaxel followed by single-agent maintenance therapy for stage III-IV or recurrent disease, for up to 20 cycles total.
Anal Carcinoma
Authorization of 6 months may be granted in either covered setting.
ANY of the following
Combination with paclitaxel and carboplatin for recurrent or metastatic anal carcinoma.
Single-agent subsequent therapy for metastatic anal carcinoma.
Anal Carcinoma, CNS Metastases, and Pancreatic Adenocarcinoma
Authorization of 6 months may be granted for any applicable disease and treatment setting.
ANY of the following
Recurrent or metastatic anal carcinoma treated with paclitaxel and carboplatin or single-agent subsequent therapy.
CNS brain metastases treated as a single agent in BRAF-nonspecific melanoma or PD-L1-positive NSCLC.
Recurrent, locally advanced, or metastatic pancreatic adenocarcinoma with MSI-H, dMMR, or TMB-H ≥10 mut/Mb disease, treated as a single agent.
Biliary Tract Cancers
Authorization of 6 months may be granted in any qualifying biliary tract cancer pathway.
ANY of the following
Locally advanced unresectable, gross residual (R2), or metastatic disease treated with gemcitabine and cisplatin or carboplatin.
Unresectable, gross residual (R2), or metastatic intrahepatic or extrahepatic cholangiocarcinoma or gallbladder cancer that is MSI-H, dMMR, or TMB-H ≥10 mut/Mb, treated as a single agent.
Neoadjuvant treatment of resectable locoregionally advanced gallbladder cancer with cisplatin or carboplatin plus gemcitabine.
Neoadjuvant single-agent treatment of resectable locoregionally advanced gallbladder cancer with MSI-H and/or dMMR disease.
Hepatocellular Carcinoma
Authorization of 6 months may be granted for hepatocellular carcinoma when ANY criterion is met.
ANY of the following
HCC secondary to hepatitis B, after prior systemic therapy other than a PD-1/PD-L1-containing regimen, treated as a single agent.
Single-agent subsequent therapy for HCC.
Additional Solid Tumor Indications
Authorization of 6 months may be granted for the following additional solid tumor indications.
ANY of the following
Advanced, recurrent, or metastatic vulvar cancer treated as subsequent single-agent therapy or with chemotherapy with or without bevacizumab.
Advanced, relapsed, or stage IV renal cell carcinoma treated first line as a single agent or with axitinib; subsequent therapy with axitinib for clear-cell disease; with lenvatinib; as a single agent for non-clear-cell disease; or adjuvantly after nephrectomy with intermediate-high or high recurrence risk or after nephrectomy and metastatic-lesion resection.
Recurrent, unresectable, advanced, or metastatic thymic carcinoma treated as a single agent, or postoperative therapy when first-line combination regimens cannot be tolerated.
Multi-agent chemotherapy-resistant gestational trophoblastic neoplasia treated as a single agent for recurrent/progressive intermediate trophoblastic tumor or high-risk disease.
Cutaneous Squamous Cell Carcinoma, Soft Tissue Sarcoma, and Occult Primary Cancer
Authorization of 6 months may be granted when the applicable disease-specific criteria are met.
ANY of the following
Locally advanced, recurrent, metastatic, or satellitosis/in-transit cutaneous squamous cell carcinoma when curative radiation or surgery is not feasible, treated as a single agent.
Soft tissue sarcoma meeting a covered subtype and regimen pathway.
Occult primary cancer with MSI-H, dMMR, or TMB-H ≥10 mut/Mb tumors, treated as a single agent.
Breast Cancer
Authorization of 6 months may be granted when all applicable biomarker and regimen criteria are met.
ANY of the following
ALL of the following
Locally recurrent unresectable or metastatic triple-negative breast cancer with HER2, estrogen, and progesterone receptor-negative testing, PD-L1 CPS ≥10, and treatment in combination with sacituzumab govitecan-hziy or chemotherapy.
ALL of the following
High-risk early-stage triple-negative breast cancer with HER2, estrogen, and progesterone receptor-negative testing.
Neoadjuvant combination with chemotherapy or continued single-agent adjuvant treatment after surgery.
Prostate Cancer and Pediatric Diffuse High-Grade Gliomas
Authorization of 6 months may be granted for the following indications.
ANY of the following
Castration-resistant distant metastatic prostate cancer with TMB ≥10 mutations/megabase, treated as a single agent.
Pediatric diffuse high-grade glioma with a hypermutant tumor treated adjuvantly, or recurrent or progressive disease treated under the covered pathway.
Prostate Cancer
Authorization of 6 months may be granted as a single agent.
ALL of the following
The member has castration-resistant distant metastatic prostate cancer.
The tumor has TMB ≥10 mutations/megabase.
Pediatric Diffuse High-Grade Gliomas
Authorization of 6 months may be granted for either qualifying condition.
ANY of the following
Adjuvant treatment of a hypermutant pediatric diffuse high-grade glioma.
Treatment of recurrent or progressive pediatric diffuse high-grade glioma.
Ampullary Adenocarcinoma
Authorization of 6 months may be granted as a single agent.
ALL of the following
The diagnosis is ampullary adenocarcinoma.
ANY of the following
TMB-H ≥10 mut/Mb disease.
Vaginal Cancer
Authorization of 6 months may be granted in either covered vaginal cancer pathway.
ANY of the following
Combination with cisplatin or carboplatin and paclitaxel, with or without bevacizumab, for recurrent or metastatic PD-L1-positive disease with CPS ≥1.
Single-agent subsequent treatment for recurrent or metastatic PD-L1-positive disease or MSI-H, dMMR, or TMB-H ≥10 mut/Mb disease.
Pleural or Peritoneal Mesothelioma
Authorization of 6 months may be granted for first-line treatment.
ALL of the following
The diagnosis is pleural or peritoneal mesothelioma, including pericardial mesothelioma or tunica vaginalis testis mesothelioma.
The requested medication is used in combination with pemetrexed and platinum chemotherapy.
Penile Cancer
Authorization of 6 months may be granted when either treatment pathway is met.
ANY of the following
First-line combination with fluorouracil and cisplatin or carboplatin, followed by single-agent maintenance therapy, for recurrent or metastatic penile cancer.
Single-agent subsequent therapy for unresectable or metastatic MSI-H, dMMR, or TMB-H ≥10 mut/Mb penile cancer.
Continuation of Therapy for Listed Cancers
Authorization of 6 months may be granted for continued treatment when the member has not experienced disease progression or unacceptable toxicity.
Applicable continuation pathway
Continued treatment for NSCLC, HNSCC, MSI-H/dMMR cancers, gastric cancer, esophageal or EGJ cancer, cervical cancer, HCC, MCC, RCC, endometrial carcinoma, cSCC, TNBC, TMB-H cancer, biliary tract cancer, pleural or peritoneal mesothelioma, penile cancer, chordoma, thyroid carcinoma, neuroendocrine or adrenal tumors, uveal melanoma, vaginal cancer, CNS brain metastases, vulvar cancer, thymic carcinoma, gestational trophoblastic neoplasia, or anal carcinoma, for up to 24 months of continuous use.
Continued treatment for a listed indication when disease has not progressed and toxicity remains acceptable.
Adjuvant Melanoma, HNSCC, TNBC, RCC, or NSCLC
Authorization of 6 months may be granted, up to 12 months total, when there has been no recurrence or unacceptable toxicity.
ANY of the following adjuvant indications
Adjuvant cutaneous melanoma.
Adjuvant triple-negative breast cancer.
Soft Tissue Sarcoma
Authorization of 6 months may be granted for continued treatment without disease progression or unacceptable toxicity.
ANY of the following
Continued treatment of alveolar soft part sarcoma in combination with axitinib, for up to 26 months total.
Continued single-agent treatment of soft tissue sarcoma, for up to 24 months total.
Cutaneous Melanoma
Authorization of 6 months may be granted for continued cutaneous melanoma treatment when the applicable duration and disease-control requirements are met.
ANY of the following
Continued adjuvant treatment after melanoma resection, up to 12 months total, without recurrence or unacceptable toxicity.
Continued treatment of metastatic or unresectable melanoma in combination with lenvatinib without progression or unacceptable toxicity.
Continued treatment of cutaneous melanoma for up to 24 months of continuous use without progression or unacceptable toxicity.
Urothelial Carcinoma
Authorization of 6 months may be granted for continued urothelial carcinoma treatment when disease control and duration requirements are met.
ANY of the following
Continued adjuvant treatment, up to 12 months total, without recurrence or unacceptable toxicity.
Continued combination treatment with enfortumab vedotin-ejfv without progression or unacceptable toxicity.
Continued urothelial carcinoma treatment for up to 24 months of continuous use without progression or unacceptable toxicity.
All Other Indications
Authorization of 6 months may be granted for continued treatment of an indication listed in the coverage criteria section when the member has not experienced disease progression or unacceptable toxicity.
ALL of the following
The indication is listed in the coverage criteria section.
The member has not experienced disease progression.
The member has not experienced unacceptable toxicity.